ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "observation"

  • Abstract Number: 679 • 2015 ACR/ARHP Annual Meeting

    Patients with Psoriatic Arthritis and Oligoarthritic Subtype Report Higher Disease Burden Than Patients with a Polyarthritic Pattern – Data from the German Collaborative Arthritis Centres

    Dörte Huscher1, Katinka Albrecht2, Sascha Bischoff2, Katja Thiele2, Frank Behrens3, Kathrin Fischer4, Ulrich von Hinüber5, Susanna Späthling-Mestekemper6, Siegfried Wassenberg7 and Angela Zink1, 1German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 2German Rheumatism Research Centre, Berlin, Germany, 3CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, 4Praxis fuer Innere Medizin, Aerztehaus Schoenwalde, Greifswald, Germany, 5Practice-based rheumatologist, Hildesheim, Germany, 6Practice-based rheumatologist, München, Germany, 7Rheumaklinik, Themistocles Gluck hospital - Rheumazentrum Ratingen, Ratingen, Germany

    Background/Purpose: Psoriatic arthritis (PsA) divides into different subtypes, of which polyarthritis and spondylitis would be expected with the highest disease severity. We compared disease burden…
  • Abstract Number: 2427 • 2014 ACR/ARHP Annual Meeting

    Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis

    Yoshiya Tanaka1, Hisashi Yamanaka2, Naoki Ishiguro3, Nobuyuki Miyasaka4, Katsuyoshi Kawana5, Katsutoshi Hiramatsu6, Aki Kuroki5 and Tsutomu Takeuchi7, 1University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 3Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 4Tokyo Medical and Dental University, Tokyo, Japan, 5Abbvie, Tokyo, Japan, 6Medical, Abbvie, Tokyo, Japan, 7Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Although available data has suggested successful withdrawal of a monoclonal antibody TNF blocker after achieving low disease activity (LDA) or remission over the short-term…
  • Abstract Number: 110 • 2014 ACR/ARHP Annual Meeting

    Use of Smartphones in Collecting Patient Reported Outcomes: Can Passively-Collected Behavior Determine Rheumatic Disease Activity? Early Results from a Nation-Wide Pilot Study

    Kaleb Michaud1,2, Sofia Pedro1, Rebecca Schumacher1, Karim Wahba3 and Sai Moturu3, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 3ginger.io, San Francisco, CA

    Background/Purpose Rheumatoid arthritis (RA) and other rheumatic diseases (RD) are associated with depression, fatigue, and disturbed sleep, symptoms that often impact behavior. Many smartphone apps…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology